A new study called PREDICT-ID Melanoma is going to assess the predictive value of immune profiles for response to the drug agent ipilimumab. The company that developed this agent, ImmunID, is a pioneer in the global immune Molecular Diagnostic (iMDx) field.
MRV Research
Experimental drugs aim to tackle melanoma ‘escape route’
Manchester researchers are developing a new generation of targeted melanoma drugs that could bypass treatment resistance seen with current therapies.
Amgen initiates study to evaluate combined talimogene laherparepvec, Keytruda for melanoma
Amgen announced the beginning of a study to evaluate the safety and efficacy of talimogene laherparepvec in combination with the investigational use of Merck’s pembrolizumab in patients with regionally or distantly metastatic melanoma, according to a press release.
Firefighters face higher risk of melanoma, prostate cancer, research shows
Male firefighters face a higher risk of melanoma and prostate cancer than the general population, researchers have found.
The study by Monash University in Melbourne looked into the potential health impacts on firefighters, through their exposure to hazardous materials.